We are a Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BEMA® Technology

A small, dissolvable polymer film for application to mucosal membranes (inner lining of cheek) which allows for transmucosal delivery of drugs.

 

CEO Dr. Mark A. Sirgo Interviewed by Jim Cramer on CNBC's Mad Money

  Click here TO WATCH

 

____________________________________

Wells Fargo 2014 Healthcare Conference

on Tuesday, June 17, 2014

at 4:40 p.m. ET

Click Here for Webcast

 __________________________________

 

William Blair & Company 2014 Growth Stock Conference 

on Wednesday, June 11, 2014

at 3:20 p.m. CT (4:20 p.m. ET)

 

 Click Here for the Webcast

 

 


 

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals


BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials
BUNAVAILâ„¢ (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3